Purpose: At present, a human epidermal growth factor receptor 2 (HER2)-based concept of tumor biology has been established, and trastuzumab (Herceptin ® ; Genentech/Roche, San Francisco, CA, USA), a monoclonal humanized antibody directed against HER2, is a pivotal agent for the management of HER2 positive (HER2+) metastatic breast cancer. It is also known that HER2 has a predictive value in gastric cancer; however, its association with the prognosis of this disease remains uncertain. The purpose of this study was to evaluate both the relationship between HER2 overexpression in the tumors of gastric cancer patients, and the prognosis of these patients who have had curative resection. Materials and Methods: A total of 139 consecutive patients with gastric cancer who underwent surgery at the Kosin University Gospel Hospital between October 2011 and March 2012 were included in this retrospective study. All tumor samples were examined for HER2 expression by immunohistochemistry. A retrospective review of the medical records was conducted to determine the correlation between the presence of HER2 overexpression and clinicopathological factors. Results: The HER2+ rate was 15.1%. HER2 overexpression was associated with histological grade (P=0.044) and Lauren classification (P=0.036). There was no significant difference in the 2-year overall survival between HER2+ and HER2-patients (P=0.396). Multivariate analysis showed that HER2 was not an independent prognostic factor. Conclusions: HER2 overexpression in tumors was associated with histological grade and Lauren classification in gastric cancer patients with curative resection. However, HER2 was not an independent prognostic factor for gastric cancer in our study.
Introduction
Gastric cancer is one of the most common and aggressive carcinomas worldwide with a high mortality, especially in South Korea. The trastuzumab for gastric cancer (ToGA) trial, has assessed human epidermal growth factor receptor 2 (HER2)-targeting agents for treating advanced gastric cancer; 1,2 and HER2 evaluation is an important approach for predicting patient response to HER2-targeting agents. Although many studies have previously evaluated HER2 status in gastric cancer, the patient cohorts and scoring criteria have varied, resulting in discrepancies in HER2 positivity that have ranged from 8.2% to 53.4%. 3 The HER2 status of South Korean gastric cancer patients currently remains uncertain. Furthermore, the association between HER2 status and prognosis in gastric cancer patients is even more unclear. The purpose of this study was to evaluate the frequency of HER2+ gastric cancer, by applying the standard scoring criteria in patients with curatively resected gastric cancer; and elucidating the relationships between HER2 expres-sion, prognosis, and clinicopathological features. 
Materials and Methods

Immunohistochemistry (IHC)
Tumor tissues were fixed in 10% formalin and embedded in paraffin. Immunohistochemical staining was carried out using anti-HER2/neu (Dako, Glostrup, Denmark) as the primary antibody for c-erbB-2. After using a microtome to cut 4 mm-thick tissue sections, the sections were immersed in xylene solution to remove residual paraffin and hydrated in an alcohol series. Sections were boiled for 5 minutes in citrate buffer (pH 6.0) to retrieve antigenicity and left for 30 minutes at room temperature. After exhausting 
Assessment of HER2 expression
The amended c-erbB-2 scoring system was applied according to location and degree of completion of staining: 0 points: staining of membrane was ≤10%; 1 point: incomplete membrane staining was ＞10%; 2 points: weak-to-moderate complete staining of the membrane; and 3 points: strong or complete staining of the membrane. An IHC score of 3+, or an IHC score of 2+ and HER2 gene amplification as detected by double-color fluorescent in situ hybridization (FISH), were defined as overexpression of HER2 ( Fig.   1 ).
Follow-up and statistical analysis
According to the study method, the Institutional Ethics Committee of the Kosin University Gospel Hospital approved the collection of survival information, for the 139 patients. Patients were asked to return for follow-up every 6 months for oncological assessment.
Data analysis was conducted using PASW Statistical Software version 18 (IBM Co., Armonk, NY, USA). The chi-squared test 
Results
Demographic characteristics
Of the 139 cases enrolled in this study, there were 90 men 
Correlation of HER2 status with clinicopathological features
The correlation between HER2 status and patient clinicopathological features is shown in analysis. HER2 positivity was not found to be an independent prognostic factor for gastric cancer (Fig. 2) .
Discussion
The c-erbB-2 gene is a proto-oncogene located on chromosome 17. It expresses HER2/neu protein, one of the epithelial growth factor receptor families, and has tyrosine kinase activity, which mediates cancer proliferation. 5 Since the overexpression of HER2 in gastric cancer was first published in 1986, 6 many studies have reported the frequency of HER2 positivity in gastric cancer patients from various regions throughout the world. According to a review by Jørgensen and Hersom, 3 the positivity rate ranged from 4% to 53% by IHC alone and from 9% to 18% when in situ hybridization (ISH) was included. Additionally, Sheng et al. 7 reported a HER2+ rate of 13%, as detected by both IHC and ISH. In the present study, the rate of HER2 positivity was estimated to be In breast cancer, genomic amplification and overexpression of the HER2 gene were also associated with poor outcomes, higher mortality, and increased higher recurrence and metastasis. [17] [18] [19] However, the association between HER2 status and prognosis in gastric cancer remains controversial, and a correlation between HER2 amplification or overexpression and favorable survival has only been shown in a few studies. [20] [21] [22] Some studies have indicated that HER2 overexpression is strongly associated with differentiated or intestinal-type gastric cancers, which generally have a better prognosis than undifferentiated or diffuse-type cancers. This may be the major source of controversies surrounding the prognostic value of HER2 overexpression. Most published studies assessing this association have shown a poor prognosis in HER2+ gastric cancers, and although reported rates of HER2 overexpression seem to be very variable, there is a general agreement about a higher HER2 positivity in gastro-esophageal junction cancer (24%~35%) than in gastric carcinoma (9.5%~21%). 8, 23, 24 In our study, no significant difference in the 2-year OS was found between HER2+ and HER2-patients. Moreover, HER2 positivity was not an independent prognostic factor by multivariate analyses.
In summary, we assessed the HER2 status in 139 samples from consecutive surgical cases of gastric cancer. The total HER2+ rate was 15.1%; and although HER2 status was found to be associated with histological grade and Lauren classification, it was not a prognostic marker for gastric cancer based on the results of our study. During the study, the Herceptin Ⓡ experimental group size (n=1) was smaller than the control group and the due to the shortterm follow-up of this group, statistical verification could not be accomplished. To produce successful results, long-term followup should be done in the future. We recognize that this study has some limitations. First, the study's follow-up-period was too short, and second, there was only one patient who used Herceptin To overcome these limitations, we think that a further randomized control study design in a large population is necessary.
In summary, we assessed the HER2 status in 139 samples of consecutive surgical cases of gastric cancer. The total HER2+ rate was 15.1%. HER2 overexpression was correlated with histological grade and Lauren classification; however, HER2 was not a prognostic marker for gastric cancer based on the results of our study.
